WARRENDALE, Pa., June 23, 2026 (GLOBE NEWSWIRE) — ECM Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K253521) for ECMT-100 WMD, a flowable extracellular matrix hydrogel intended for the management of wounds.
The clearance represents a significant milestone for ECM Therapeutics and reflects decades of scientific advancement in extracellular matrix-based technologies led by Stephen F. Badylak, DVM, MD, PhD, Chief Medical Officer of ECM Therapeutics and a pioneer in the field of regenerative medicine. Dr. Badylak’s research has helped establish the scientific foundation for the use of extracellular matrices in a wide range of clinical applications and has contributed to the development of numerous commercially available medical products across multiple surgical specialties.
← Back to News